BioPharmSignal logoBioPharmSignal

Biotech News

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

Jaguar Health (JAGX)Jaguar HealthPartnership

As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi ® and Canalevia ® -CA1 - Jaguar's two commercialized crofelemer drugs - an agreement that is fully aligned with company's strategy to

Related news

JAGXJaguar Health2026-04-07 12:30 EST

Jaguar Health Reports 2025 Financials

JAGXJaguar Health2026-04-29 12:30 EST

Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs

IBRXImmunityBio2026-04-21 11:30 EST

ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership

SCYXSCYNEXIS2025-11-17 15:15 EST

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

IBRXImmunityBio2026-03-31 11:30 EST

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

HROWHarrow, Inc.2026-06-10 11:00 EST

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

HROWHarrow, Inc.2026-02-02 12:00 EST

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

ALZNAlzamend Neuro2026-08-04 12:00 EST

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

View all latest news

Jaguar Health

Jaguar Health is a biopharmaceutical company focused on gastrointestinal and rare-disease therapies, with Mytesi as a key commercial asset. Its story combines niche commercialization with a pipeline aimed at high-unmet-need GI indications.

Recent company news

JAGXJaguar Health2026-08-18 13:00 EST

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates

JAGXJaguar Health2026-08-05 13:00 EST

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

JAGXJaguar Health2026-07-28 13:00 EST

Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog

JAGXJaguar Health2026-07-22 13:00 EST

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)

JAGXJaguar Health2026-06-30 13:00 EST

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)

Stock data

Close
0.88 USD
Market cap
2.12M USD
Exchange
NASDAQ
Sector
Biopharma
Location
San Francisco, California